Compare BioNano Genomics Inc (BNGO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Stanley Black & Decker, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Stanley Black & Decker, Inc. trades at $88.24 (market cap $13.58B). The key difference: Stanley Black & Decker, Inc. is far larger — about 1028.8× BioNano Genomics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.8% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SWK | |
|---|---|---|
Market Cap | $13.20M | $13.58B |
Sector | Health | — |
52-Week High | $4.92 | $94.12 |
52-Week Low | $1.09 | $62.12 |
Enterprise Value | $15.81M | $19.75B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Stanley Black & Decker (SWK) trades at $86.53, down 1.92% on the day, with a bearish technical signal but recent earnings beats. The company shows modest revenue of $15.13B in 2025 and a net income margin of 2.44%, though profitability metrics like ROE at 4.17% remain subdued. A dividend of $0.83 was recently declared, with cash flow from operations positive at $971.20M. Analyst consensus is mixed with 43% buy ratings but a price target below the current price.
SWK faces headwinds from weak Tools & Outdoor demand and high debt, though cost-saving efforts and aerospace growth offer upside. The stock's valuation at a P/E of 35.46 appears stretched relative to earnings growth, suggesting cautious optimism hinges on execution improvements and debt reduction. Risks include consumer sentiment and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
